EUVIMEDEUVIMED entdecken
Crossref

Preclinical ImmunoPET Imaging of Thyroid-Stimulating Hormone Receptor Expression in Thyroid Cancer using [ 64 Cu]Cu-NOTA-TSHR-Ab

Wenhui Fu, Ephraim E Parent, Justyna J Gleba, Joshua A Knight, Otto Muzik, John A Copland, Hancheng Cai iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Wenhui Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Jacksonville, Florida 32224, United States. Hauptthemen laut MEDLINE: Copper Radioisotopes, Receptors, Thyrotropin, Thyroid Neoplasms, Positron-Emission Tomography. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Florida Department of Health, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced thyroid cancers are aggressive and often refractory to the current standard of care. The thyroid-stimulating hormone receptor (TSHR) is highly expressed in thyroid cancers and rarely expressed outside the thyroid, making it a viable target for developing radiotheranostics for imaging and therapy of advanced thyroid cancer. This study reports the radiosynthesis and preclinical evaluation of a 64Cu-labeled human antibody for positron emission tomography (PET) imaging of TSHR expression in advanced thyroid cancer mouse models. Human anti-TSHR recombinant antibody K1-70 (TSHR-Ab) was labeled with copper-64, yielding [64Cu]Cu-NOTA-TSHR-Ab with a radiochemical yield of 46.89 ± 3.74%, radiochemical purity of 98.77 ± 0.89%, and specific activity >212 GBq/μmol (n = 5). In vitro studies on TSHR-positive (THJ529TTSHR+) and wild-type (THJ529TWT) cells demonstrated the radiotracer's high specificity and nanomolar binding affinity for THJ529TTSHR+ cells, with a dissociation constant (Kd) of 4.74 nM and an inhibition constant (Ki) of 0.92 nM. ImmunoPET imaging in mice bearing dual-flank tumors (THJ529TWT and THJ529TTSHR+) at multiple time points (1, 2, 4, 18, 24, and 48 h) postinjection (p.i.) revealed rapid tumor targeting and high uptake in TSHR-positive thyroid tumors (SUVmax: 3.63 ± 0.42, 3.82 ± 0.44, and 4.09 ± 0.56 at 18, 24, and 48 h p.i., respectively). Co-injection studies with varying doses of unlabeled TSHR-Ab (0, 25, 50, 100 μg) demonstrated that the coinjection significantly reduced background signals, especially in the spleen, liver, and bone, with a dose of 25 μg effectively reducing off-target signals without affecting tumor uptake. Biodistribution and immunohistochemistry analyses supported these immunoPET imaging results. Furthermore, a comparison study with traditional [18F]FDG PET imaging showed that [64Cu]Cu-NOTA-TSHR outperformed [18F]FDG in tumor detection. In conclusion, [64Cu]Cu-NOTA-TSHR-Ab is a promising radiotracer for PET imaging of TSHR-positive advanced thyroid cancers, with the potential to guide and monitor TSHR-targeted therapies. Further clinical evaluation of [64Cu]Cu-NOTA-TSHR-Ab could provide valuable insights for patient stratification and optimization of anti-TSHR treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Copper RadioisotopesReceptors, ThyrotropinThyroid NeoplasmsPositron-Emission TomographyAnimalsMiceHumansRadiopharmaceuticalsTissue DistributionCell Line, TumorFemaleHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Stichwörter der Autor:innen

advanced thyroid cancerantibodycopper-64positron emission tomography (PET)thyroid-stimulating hormone receptor (TSHR)

Substanzen

Copper RadioisotopesReceptors, ThyrotropinRadiopharmaceuticalsCopper-641,4,7-triazacyclononane-N,N',N''-triacetic acidHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Radiology, Mayo Clinic, Jacksonville, Florida 32224, United States.
  • Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida 32224, United States.
  • Department of Neurology, Wayne State University, Detroit, Michigan 48201, United States.
  • Department of Pediatrics, Wayne State University, Detroit, Michigan 48201, United States.
  • PET Center, Karmanos Cancer Institute, Detroit, Michigan 48201, United States.

ORCID-Profile: Hancheng Cai

Förderung

  • Florida Department of Health
  • Mayo Clinic

Zitieren

APA

Fu, W., Parent, E. E., Gleba, J. J., Knight, J. A., Muzik, O., Copland, J. A., & Cai, H. (2025). Preclinical ImmunoPET Imaging of Thyroid-Stimulating Hormone Receptor Expression in Thyroid Cancer using [ 64 Cu]Cu-NOTA-TSHR-Ab. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00325

Vancouver

Fu W, Parent EE, Gleba JJ, Knight JA, Muzik O, Copland JA, et al. Preclinical ImmunoPET Imaging of Thyroid-Stimulating Hormone Receptor Expression in Thyroid Cancer using [ 64 Cu]Cu-NOTA-TSHR-Ab. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00325

BibTeX
@article{Fu2025,
  author = {Fu, Wenhui and Parent, Ephraim E and Gleba, Justyna J and Knight, Joshua A and Muzik, Otto and Copland, John A and Cai, Hancheng},
  title = {Preclinical ImmunoPET Imaging of Thyroid-Stimulating Hormone Receptor Expression in Thyroid Cancer using [ 64 Cu]Cu-NOTA-TSHR-Ab},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00325}
}
Kostenlos starten →